News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

01/04/2018 | CureVac AG

CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeuti...
12/07/2017

Hope in the fight against multi-resistant germs

Researchers from the Universities of Stuttgart and Tübingen prove the effectiveness of new types of antibiotics.
12/06/2017

Microalgae Ready for Space

The University of Stuttgart hands over photobioreactor chambers for space experiment on the ISS
12/06/2017

Nerve Cells on the ISS: University of Hohenheim Examines How Cells Grow without Gravity

Project NEUROBOX sends human nerve cells to the International Space Stations / Project looks at how nervous systems develop in space / Team accompanies mission with journals How would the first person born in space develop? While it sounds like a question for a science fiction novel, it is the background of a current research project at the Univers...
10/19/2017 | CureVac AG

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types / CureVac to receive an upfront payment of $50 million and an equity investment of €45 million
08/21/2017 | immatics biotechnologies GmbH

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA1...
08/16/2017 | CureVac AG

Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

Data validate the strength of CureVac’s RNAntibody® technology to produce high and sustained levels of antibody production in a variety of disease indications
07/26/2017

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

Data from phase I clinical trial of CureVac’s RNActive® prophylactic vaccine technology in rabies demonstrates for the first time an induction of boostable functional antibodies against a viral antigen when administered via needle-free injection Cu...
07/24/2017 | CureVac AG

CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies

Patent covers Composition of Matter and Methods of Treatment for vaccine/inhibitor combination for the prevention or treatment of cancer and infectious diseases
06/28/2017 | CureVac AG

CureVac Expands GMP Production Capacities for RNA Products

Supply for Full RNA Clinical Pipeline and Later Commercialization Secured CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced during a public open door event at its main location in Tübingen, Germany, on June 24 the extension of its GMP production capabilities to meet the clinical and futur...
06/25/2017

Medicxi launches first $300m late-stage life sciences fund Medicxi Growth 1 (MG1), backed by Novartis and Verily

Medicxi announced on June 15th the close of Medicxi Growth 1 (MG1), a new $300 million fund that will focus on growth stage companies in European life sciences.
06/21/2017

CeGaT Obtains CLIA Certification, Final Step Towards U.S. Market Entry

CeGaT GmbH, a leading global genetic testing provider focused on large panel and trio-exome diagnostics, has obtained its CLIA certification. After receiving CAP accreditation in 2016, CeGaT has been granted Clinical Laboratory Improvement Amendments (CLIA) certification by The Centers for Medicare & Medicaid Services (CMS), ensuring complian...
06/14/2017 | CureVac AG

CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

Patents granted for mRNA-based RSV vaccines as well as for vaccination of infants / newborns and elderly with mRNA-based vaccines such as Flu CureVac AG a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has been granted important patents claiming the use of mRNA-based prophylactic vaccines, significantly add...
05/02/2017 | CureVac AG

CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, today announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston based U.S. subsidiary. Mr. Menichella, an experienced executive in the biotech-industry, will develop CureVac’s US organization with a clear focus on business an...
04/12/2017 | Exyte

M+W Group names new CEO for the Americas Region

Rick Whitney has been named CEO of M+W Group’s Americas Region and President of the company’s subsidiary M+W U.S. Inc. Whitney brings extensive industry expertise to his second stint at M+W Group, where he worked from 1997 to 2014.
04/12/2017 | Curetis GmbH

Curetis erweitert Aufsichtsrat und Medizinischen Beirat

Dr. Nils Clausnitzer für Aufsichtsratsmitgliedschaft nominiert; Dr. Melissa Miller in Medizinischen Beirat aufgenommen
03/29/2017 | Exyte

M+W Group Promotes Smart Lab Design at the Asia Pharma R&D Leaders Summit 2017

M+W Group was invited as a thought leadership company to participate in the Asia Pharma R&D Leaders Summit 2017, a key pharma R&D event in China, being held in Shanghai, China.
03/16/2017 | Exyte

M+W Group on a Successful Streak with Semiconductor Awards

Leading global high-tech engineering company, M+W Group is celebrating their recent successes in semiconductor projects with awards in both China and Taiwan.